Abcam launches new checkpoint inhibitor clone

Cambridge, UK-based life sciences firm Abcam (AIM: ABC) has announced the commercial launch of a new anti-PD-L1 antibody clone, dubbed MKP1A07310, developed in collaboration with Germany’s Merck KGaA (MRK: DE).

Abcam says it developed the clone, a key antibody in assessing the expression of PD-L1 in tumors, for Merck to use in support of its therapeutic program several years ago.

Senior vice president John Baker said: “Collaborations with industry partners are an important part of Abcam’s strategy to provide the best tools to all researchers worldwide. By working with Merck we are able to make available this important antibody at scale to help scientists accelerate their research, and expand understanding of the role of immune checkpoint inhibitors as cancer therapeutics.”